Neuronetics, Inc. (NASDAQ:STIM – Get Free Report) Director Glenn P. Muir bought 12,776 shares of the stock in a transaction dated Wednesday, August 28th. The stock was bought at an average cost of $0.85 per share, for a total transaction of $10,859.60. Following the acquisition, the director now directly owns 252,594 shares of the company’s stock, valued at approximately $214,704.90. The purchase was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink.
Neuronetics Stock Up 3.9 %
Shares of NASDAQ STIM opened at $0.88 on Friday. The company has a current ratio of 2.58, a quick ratio of 2.37 and a debt-to-equity ratio of 2.38. Neuronetics, Inc. has a 12-month low of $0.66 and a 12-month high of $5.07. The firm’s 50-day moving average price is $1.57 and its 200-day moving average price is $2.66. The stock has a market capitalization of $26.49 million, a price-to-earnings ratio of -0.92 and a beta of 2.32.
Neuronetics (NASDAQ:STIM – Get Free Report) last posted its quarterly earnings data on Monday, August 12th. The company reported ($0.33) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.27) by ($0.06). The company had revenue of $16.45 million during the quarter, compared to the consensus estimate of $18.76 million. Neuronetics had a negative net margin of 45.06% and a negative return on equity of 109.00%. During the same period in the previous year, the business earned ($0.17) earnings per share. On average, equities research analysts anticipate that Neuronetics, Inc. will post -0.87 EPS for the current fiscal year.
Institutional Investors Weigh In On Neuronetics
Wall Street Analyst Weigh In
STIM has been the topic of several research analyst reports. Canaccord Genuity Group decreased their price target on shares of Neuronetics from $6.00 to $3.00 and set a “buy” rating on the stock in a research note on Tuesday, August 13th. William Blair reiterated a “market perform” rating on shares of Neuronetics in a research report on Monday, August 12th. Finally, JMP Securities reduced their price objective on Neuronetics from $7.00 to $3.00 and set a “market outperform” rating on the stock in a research note on Wednesday, August 14th.
Read Our Latest Stock Analysis on STIM
Neuronetics Company Profile
Neuronetics, Inc, a commercial stage medical technology company, designs, develops, and markets products for patients with neurohealth disorders in the United States and internationally. The company offers NeuroStar Advanced Therapy System, a non-invasive and non-systemic office-based treatment to treat adult patients with major depressive disorder.
Further Reading
- Five stocks we like better than Neuronetics
- How to Effectively Use the MarketBeat Ratings Screener
- Birkenstock’s Sudden Slide—Why It Might Be Your Next Big Win
- Best Stocks Under $5.00
- Why Dell Can Continue Winning in AI and Beyond
- What is an Earnings Surprise?
- Veeva’s Stock Jumps on Stellar Q2 Results—Don’t Miss Out
Receive News & Ratings for Neuronetics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Neuronetics and related companies with MarketBeat.com's FREE daily email newsletter.